SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Nuvo Research Inc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DaveAu who wrote (13637)9/23/2004 4:16:39 AM
From: axial   of 14101
 
"There are so many other stocks out there. I can't see why anyone wants to buy this one. It is an interesting story however."

History and appearances support your conclusion.

If you're correct, there's is no possibility of FDA approval for Pennsaid. No possibility that the reality of WF10 is not understood, and that it will demonstrate usefulness in Hep C and cancer. No possibility that Penecure will become a viable product. No possibility that Oxo Chemie's products can improve their contribution to revenues. No future for Oxoferin. No possibility of adjusting the price of Pennsaid, and improving its acceptance by formularies.

This is it. Under new management, we won't see $0.40 become $0.80, $1.20, or $4.00. No chance of a double, never mind a triple.

That's the call, and that's what makes a market.

Cheers,

Jim
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News